scholarly article | Q13442814 |
P819 | ADS bibcode | 2016PLoSO..1168376P |
P356 | DOI | 10.1371/JOURNAL.PONE.0168376 |
P932 | PMC publication ID | 5172579 |
P698 | PubMed publication ID | 27997580 |
P50 | author | Cristina Scarpazza | Q62058593 |
Luca Prosperini | Q64878102 | ||
P2093 | author name string | Ruggero Capra | |
Mirco Cosottini | |||
Simonetta Gerevini | |||
Lucia Moiola | |||
Italian PML study group | |||
Nicola de Rossi | |||
P2860 | cites work | Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 |
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring | Q22242013 | ||
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain | Q24619923 | ||
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives | Q26776236 | ||
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society | Q59389216 | ||
Kurtzke scales revisited: the application of psychometric methods to clinical intuition | Q73699544 | ||
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy | Q84114256 | ||
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group | Q26780412 | ||
Neurological immune reconstitution inflammatory response: riding the tide of immune recovery | Q28082309 | ||
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring | Q28243804 | ||
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis | Q30278095 | ||
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
Inflammatory Reaction in Progressive Multifocal Leukoencephalopathy: Harmful or Beneficial? | Q30787765 | ||
The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology | Q30787783 | ||
Progressive multifocal leukoencephalopathy in HIV-1 infection | Q33506561 | ||
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis | Q33893285 | ||
Persistence and pathogenesis of the neurotropic polyomavirus JC | Q34459843 | ||
Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab | Q34556743 | ||
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients | Q34562841 | ||
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. | Q34803324 | ||
Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 | ||
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS | Q35938575 | ||
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 | ||
Diagnostic delay in progressive multifocal leukoencephalopathy | Q36891735 | ||
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 | ||
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis | Q38089536 | ||
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy | Q39418067 | ||
Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases | Q40922077 | ||
Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay | Q40994617 | ||
MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. | Q41361912 | ||
MRI pattern in asymptomatic natalizumab-associated PML. | Q41745436 | ||
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis | Q42268433 | ||
Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? | Q43897444 | ||
Variations in functioning and disability in multiple sclerosis. A two-year prospective study | Q45138514 | ||
Anti-JC virus antibodies: implications for PML risk stratification | Q45373492 | ||
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. | Q46007698 | ||
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis | Q47202056 | ||
Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab | Q48119795 | ||
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients | Q48386105 | ||
The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? | Q48401612 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Italy | Q38 |
progressive multifocal leukoencephalopathy | Q704930 | ||
multiple sclerosis | Q8277 | ||
P304 | page(s) | e0168376 | |
P577 | publication date | 2016-01-01 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry | |
P478 | volume | 11 |
Q40100891 | Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. |
Q39409318 | Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis |
Q41455235 | Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions |
Q39391443 | Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis |
Q42363059 | Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy |
Q91830971 | Progressive Multifocal Leukoencephalopathy: Current Insights |
Q45325710 | The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy. |
Q58864832 | The still under-investigated role of cognitive deficits in PML diagnosis |
Q47812653 | To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. |
Q90288758 | Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration |
Q64274762 | Treatment of natalizumab-associated PML with filgrastim |
Search more.